What HOB Biotech does

HOB Biotech (浩欧博), legally Jiangsu HOB Biomedical Co., Ltd., is a Suzhou-headquartered in vitro diagnostics company founded in 2009 and listed on the Shanghai Stock Exchange STAR Market (科创板) under stock code 688656 in January 2021. The company is now a controlled subsidiary of China Biopharmaceuticals (HK01177), which became the actual controller in late 2024. HOB specializes in allergy and autoimmune disease diagnostics, operating across four core technology platforms: magnetic microparticle chemiluminescence immunoassay (the proprietary Naboc/纳博克 platform), immunoblotting (Minboc/敏博克, Western blot), enzyme-linked immunosorbent assay (Fuboc/符博克), and indirect immunofluorescence. Its assay menu spans 103 allergen items and 60+ autoimmune antibody items covering 9 disease systems, supported by an installed base of automated analyzers ranging from the high-throughput Venus 9500 HOB (up to 3,600T/h networked) to the BioCLIA 1900/6900/6500/500 series.

The company earns revenue through three streams: (1) sale of IVD reagent kits for specific IgE, food-specific IgG, and autoimmune antibodies (recurring consumables tied to the installed analyzer base); (2) sale and service of automated chemiluminescence and supporting instruments (hardware sales); and (3) sale of ORALTEK (欧脱克) sublingual spray desensitization drugs imported from Europe, covering 17 allergen types and distributed through the Hainan Boao Lecheng and Greater Bay Area pilot zones. Go-to-market is a direct enterprise field sales motion covering all 34 Chinese provinces and municipalities, serving 3,000+ hospitals including 700+ tertiary (Grade 3A) hospitals, combined with a channel-partner motion across 20+ countries internationally (UK, France, Germany, Spain, Saudi Arabia, Iraq, Singapore, Malaysia, India, Colombia) and event-driven academic marketing through conferences such as CACLP. Pricing follows a quote-based institutional B2B model with multi-year contracts; no public pricing is disclosed.

HOB's customer base is anchored by hospital clinical laboratories and Grade 3A/3B hospitals, with named flagship relationships including Peking Union Medical College Hospital for clinical validation. The company holds 200+ NMPA product registrations, has earned NCRC proficiency testing full-score certification for 10 consecutive years, and was designated a 2024 National Specialized, Refined, and New 'Little Giant' Enterprise. Value proposition centers on being the first STAR Market-listed allergy diagnostics company in China, the only domestic provider of an integrated diagnosis-to-treatment closed loop, and the holder of the most comprehensive allergen detection menu in the Chinese market.

Name

HOB Biotech

Legal name

江苏浩欧博生物医药股份有限公司

Website

https://hob-biotech.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

HOB Biotech (浩欧博) is a Suzhou-headquartered, STAR Market-listed (688656) in vitro diagnostics company specializing in allergy and autoimmune disease testing via chemiluminescence, ELISA, and Western blot platforms, serving 3,000+ hospitals in China and 20+ countries internationally, and now operating as a subsidiary of China Biopharmaceuticals (HK01177).

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Autoimmune & Allergy Diagnostics (HLAAALAK)

akta.pro secondary industries

Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Food Allergy Evaluation & Management (HLAKAAAD)

Keywords

• Allergy diagnostics
• Autoimmune diagnostics
• In vitro diagnostics
• Chemiluminescence immunoassay
• Sublingual immunotherapy

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. In Vitro Diagnostic Reagents: Sale of allergy and autoimmune disease diagnostic reagents including test kits for specific IgE antibodies, food-specific IgG antibodies, and autoimmune antibodies
2. Instrument Sales and Service: Sale and service of automated chemiluminescence analyzers (BioCLIA series, Venus 9500 HOB) and supporting equipment
3. Desensitization Treatment Products: Sale of ORALTEK sublingual spray desensitization drugs imported from Europe, covering 17 allergen types, available in Hainan Boao Lecheng and Greater Bay Area

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

HOB Biotech researches, develops, and manufactures in vitro diagnostic reagents and automated immunoassay analyzers for allergy (specific IgE, food-specific IgG, component-resolved diagnostics) and autoimmune disease (autoantibody panels covering 9 disease systems) testing, alongside European-origin ORALTEK sublingual spray desensitization therapy. Its products are sold to hospital clinical laboratories and third-party testing facilities in China and internationally.

Differentiator

Problem solved

Functional benefit

Brands

• 纳博克 (Naboc/纳博克): Magnetic microparticle chemiluminescence platform for allergy and autoimmune disease quantitative detection, including Venus 9500 HOB, BioCLIA 6900, BioCLIA 1900 automated analyzers and associated reagent kits.
• 敏博克 (Minboc)
• 符博克 (Fuboc)
• 欧博克 (Ouboc)
• 食博克 (Shiboc/食博克)
• 欧脱克 (Outuo/ORALTEK)
• BioCLIA

Products and services

• 纳博克 (Naboc) Magnetic Microparticle Chemiluminescence Allergy and Autoimmune Diagnostic Reagent Series A magnetic microparticle chemiluminescence immunoassay (CLIA) reagent product line for quantitative detection of allergen-specific IgE, food-specific IgG, and autoimmune antibodies, used by hospital clinical laboratories and diagnostic centers.
• BioCLIA Series Fully Automated Chemiluminescence Immunoassay Analyzers (BioCLIA 1900 / BioCLIA 6900 / Venus 9500 HOB / BioCLIA 6500 / BioCLIA 500) Automated chemiluminescence immunoassay analyzer instruments with throughput up to 900T/h per single unit and 3600T/h when networked; sample volumes as low as 6μL for IgG detection; used by hospital and reference laboratories to run HOB's chemiluminescence reagent menu.
• 敏博克 (Minboc) Immunoblot (Western Blot) Allergy and Autoimmune Diagnostic Series Immunoblot (Western blot)-based diagnostic reagent kits for allergy and autoimmune disease testing, sold to hospital clinical laboratories as an alternative platform to the chemiluminescence line.
• 符博克 (Fuboc) ELISA Allergen-Specific IgE Quantitative Detection Series Enzyme-linked immunosorbent capture assay (ELISA) reagent kits for quantitative allergen-specific IgE detection, sold to hospital clinical laboratories with 46 quantitative allergen items.
• 欧博克 (Ouboc) Traditional ELISA Allergen-Specific IgE Detection Reagent Series Traditional ELISA-based allergen-specific IgE detection reagent kits for hospital laboratories preferring classical ELISA methodology.
• 食博克 (Shiboc) Food-Specific IgG Antibody Detection Series ELISA-based reagent kits for detecting food-specific IgG antibodies to identify food sensitivities, used by hospital clinical laboratories and food intolerance testing services.
• 欧脱克 (ORALTEK) Sublingual Spray Desensitization Therapy Product European-origin sublingual spray desensitization drug covering 17 allergen types for allergen immunotherapy treatment of allergic rhinitis, allergic conjunctivitis, and allergic asthma; imported by HOB and distributed in China including at the Hainan Boao Lecheng International Medical Tourism Pilot Zone and Greater Bay Area.

Quantifiable outcome

• 连续10年NCRC室间质评全满分通过，46项自免+17项过敏原项目全部合格
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• Peking Union Medical College Hospital (北京协和医院)coreStrategic or Co-development PartnerClinical validation partnership for allergy diagnostic products; validation of符博克 system performance using CLSI EP protocol
• 金域医学 (GACLS Medical)coreStrategic or Co-development PartnerStrategic partnership for third-party laboratory testing services; collaboration to extend allergy testing services to grassroots healthcare institutions
• European Supplier (ORALTEK)coreOEM/ Whitelabel/ Licensing PartnerIn 2023, HOB introduced ORALTEK sublingual spray desensitization drugs from Europe, covering 17 allergen types, available at Hainan Boao Lecheng International Medical Tourism Pilot Zone and Greater Bay Area
• National Clinical Research Center for Respiratory Diseases / Guangzhou Medical University First Affiliated HospitalcoreStrategic or Co-development PartnerHOB作为协办单位参与CARRAD III全国过敏流行病学调查项目，提供纳博克磁微粒化学发光平台进行过敏原sIgE检测支持
• International Distributors (UK, France, Germany, Spain, Saudi Arabia, Iraq, Singapore, Malaysia, India, Colombia)coreChannel Partner/ Reseller/ Distributor20+ countries covered through international distribution network; participation in international exhibitions including MEDLAB Dubai and ICA Athens

Scale indicators10 records

Recent moves11 records

Expansion highlights6 records

Others

• KingMed Diagnostics (金域医学): Largest independent third-party medical laboratory network in China (Shanghai: 603882); HOB's third-party laboratory partner for extending allergy testing services to grassroots institutions. Customer and channel partner rather than direct reagent competitor.

Direct peers

• Maccura Biotechnology (迈克生物): Publicly listed Chinese IVD company (Shenzhen: 300463) with chemiluminescence and ELISA reagent lines serving hospital labs. Direct competitor across allergy, autoimmune, infectious disease, and biochemistry testing reagents.
• Autobio Diagnostics (安图生物): Publicly listed Chinese IVD company (Shanghai: 603658) operating automated chemiluminescence immunoassay analyzers and a broad infectious-disease, tumor-marker and specialty reagent menu. Competes with HOB for the same hospital laboratory customers.
• Shenzhen New Industries Biomedical Engineering (Snibe / 新产业生物): Publicly listed Chinese chemiluminescence immunoassay IVD leader (Shenzhen: 300832) with a comparable CLIA platform and reagent menu serving hospital laboratories in China and globally. Most direct domestic competitor on the technology axis HOB depends on.
• Hycor Biomedical (Agilent Technologies): Allergy and autoimmune in vitro diagnostics specialist (acquired by Agilent in 2022), offering the NOVEOS and previous-generation IgE testing platforms. Closest international peer on the allergy IVD technology and menu breadth.
• EUROIMMUN (Revvity / PerkinElmer): Global autoimmune diagnostics leader (now part of Revvity, formerly PerkinElmer) with the broadest autoantibody test menu worldwide. Closest international competitor in HOB's autoimmune disease diagnostics business.

Broad incumbents

• Thermo Fisher Scientific (Phadia / ImmunoCAP): Global leader in allergy diagnostics through its Phadia/ImmunoCAP franchise, the dominant quantitative allergen-specific IgE platform worldwide. Sets the technical benchmark HOB's CLIA platforms must match in Chinese tertiary hospitals.
• Mindray (迈瑞医疗): Largest Chinese medical-device and IVD incumbent (Shenzhen: 300760) with broad chemistry, immunoassay, hematology and microbiology reagent portfolios. Competes with HOB for hospital lab budgets at a larger scale and broader product set.
• Abbott Diagnostics: Major global diagnostics incumbent with broad immunoassay, allergy, and infectious disease menus. Competes with HOB primarily in higher-tier Chinese hospital labs through its Architect/Alinity platforms.

Emerging players

• AESKU Diagnostics: Germany-based specialty IVD company focused on allergy and autoimmune diagnostics with a broad autoantibody and allergen menu. Comparable scale and focus area to HOB outside the Chinese market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HOB Biotech